Double Delight For Novartis At The CHMP
Backing For MS Drug Mayzent And Isturisa For Cushing's
Executive Summary
Novartis has received two positive opinions in Europe, the most important being for Mayzent, its active secondary progressive multiple sclerosis drug which is key to the company's ambitions for growth in the neurology space.
You may also be interested in...
Recordati's Isturisa Approved For Cushing's In EU
Acquired from Novartis last year, Isturisa is forecast to have peak sales of over $100m. Now all eyes will be on a PDUFA date in March.
FDA Backs Novartis MS Pill Mayzent With Broad Label
Mayzent is the first oral therapy proven to delay progression in patients with secondary progressive multiple sclerosis and Novartis pharma chief Paul Hudson tells Scrip its $88,500 list price will not affect access.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.